GERM
Amplify Treatments, Testing and Advancements ETF
GERM
GERM
Delisted
GERM was delisted on the 5th of September, 2024.
17 hedge funds and large institutions have $3.43M invested in Amplify Treatments, Testing and Advancements ETF in 2023 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 3 reducing their positions, and 4 closing their positions.
New
Increased
Maintained
Reduced
Closed
more capital invested
Capital invested by funds: $ → $
less funds holding
Funds holding: →
less repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
less first-time investments, than exits
New positions opened: | Existing positions closed:
Holders
17
Holding in Top 10
–
Calls
–
Puts
–
Top Buyers
| 1 | +$667K | |
| 2 | +$579K | |
| 3 | +$246K | |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$50.5K |
Top Sellers
| 1 | -$339K | |
| 2 | -$260K | |
| 3 | -$240K | |
| 4 |
Commonwealth Equity Services
Waltham,
Massachusetts
|
-$54K |
| 5 |
BAM
Belpointe Asset Management
Reno,
Nevada
|
-$36.5K |